293 related articles for article (PubMed ID: 11709321)
1. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients.
Sajjan US; Tran LT; Sole N; Rovaldi C; Akiyama A; Friden PM; Forstner JF; Rothstein DM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3437-44. PubMed ID: 11709321
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
McCaughey G; McKevitt M; Elborn JS; Tunney MM
J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
[TBL] [Abstract][Full Text] [Related]
3. Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients.
Aichele D; Schnare M; Saake M; Röllinghoff M; Gessner A
Infect Immun; 2006 Aug; 74(8):4708-14. PubMed ID: 16861658
[TBL] [Abstract][Full Text] [Related]
4. Bacterial cyanogenesis occurs in the cystic fibrosis lung.
Sanderson K; Wescombe L; Kirov SM; Champion A; Reid DW
Eur Respir J; 2008 Aug; 32(2):329-33. PubMed ID: 18480103
[TBL] [Abstract][Full Text] [Related]
5. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
King P; Citron DM; Griffith DC; Lomovskaya O; Dudley MN
Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274
[TBL] [Abstract][Full Text] [Related]
6. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis.
Reid DW; Carroll V; O'May C; Champion A; Kirov SM
Eur Respir J; 2007 Aug; 30(2):286-92. PubMed ID: 17504792
[TBL] [Abstract][Full Text] [Related]
7. Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis.
Gillham MI; Sundaram S; Laughton CR; Haworth CS; Bilton D; Foweraker JE
J Antimicrob Chemother; 2009 Apr; 63(4):728-32. PubMed ID: 19193658
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas-infected cystic fibrosis patient sputum inhibits the bactericidal activity of normal human serum.
Schiller NL; Millard RL
Pediatr Res; 1983 Sep; 17(9):747-52. PubMed ID: 6413945
[TBL] [Abstract][Full Text] [Related]
9. Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum.
Dubois AV; Midoux P; Gras D; Si-Tahar M; Bréa D; Attucci S; Khelloufi MK; Ramphal R; Diot P; Gauthier F; Hervé V
Am J Respir Crit Care Med; 2013 Sep; 188(6):703-9. PubMed ID: 23947381
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
[TBL] [Abstract][Full Text] [Related]
11. Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum.
Palmer KL; Aye LM; Whiteley M
J Bacteriol; 2007 Nov; 189(22):8079-87. PubMed ID: 17873029
[TBL] [Abstract][Full Text] [Related]
12. Potential therapeutic role of histatin derivative P-113d in experimental rat models of Pseudomonas aeruginosa sepsis.
Cirioni O; Giacometti A; Ghiselli R; Orlando F; Kamysz W; D'Amato G; Mocchegiani F; Lukasiak J; Silvestri C; Saba V; Scalise G
J Infect Dis; 2004 Jul; 190(2):356-64. PubMed ID: 15216473
[TBL] [Abstract][Full Text] [Related]
13. Stability and activity in sputum of G10KHc, a potent anti-Pseudomonas antimicrobial peptide.
Eckert R; Mchardy I; Yarbrough DK; He J; Qi F; Anderson MH; Shi W
Chem Biol Drug Des; 2007 Nov; 70(5):456-60. PubMed ID: 17927719
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
[TBL] [Abstract][Full Text] [Related]
15. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
Hansen CR; Pressler T; Hoiby N; Johansen HK
J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
[TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa and Burkholderia cenocepacia infections in patients affected by cystic fibrosis: serum resistance and antibody response.
Savoia D; Deplano C; Zucca M
Immunol Invest; 2008; 37(1):19-27. PubMed ID: 18214797
[TBL] [Abstract][Full Text] [Related]
17. The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa.
Barth AL; Pitt TL
J Med Microbiol; 1996 Aug; 45(2):110-9. PubMed ID: 8683546
[TBL] [Abstract][Full Text] [Related]
18. Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
Kronborg G
APMIS Suppl; 1995; 50():1-30. PubMed ID: 7756034
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa, cyanide accumulation and lung function in CF and non-CF bronchiectasis patients.
Ryall B; Davies JC; Wilson R; Shoemark A; Williams HD
Eur Respir J; 2008 Sep; 32(3):740-7. PubMed ID: 18480102
[TBL] [Abstract][Full Text] [Related]
20. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND
Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
